CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
- CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
The issuer is solely responsible for the content of this announcement.
- The vaccine candidate elicited balanced humoral and cellular immune responses, featuring high antibody titers and very good T cell activation.
- In addition to the positive immune response, the vaccine candidate induced favorable Th1 cytokine levels.
- The full manuscript of the preclinical data is available on the pre-print server bioRxiv and was submitted for potential publication in a peer-reviewed journal.